HEAT-PPCI: Heparin Bests Bivalirudin in STEMI, Amid Heated DebateHEAT-PPCI: Heparin Bests Bivalirudin in STEMI, Amid Heated Debate
The HEAT-PPCI took heat like no other trial on the last day of the ACC 2014 meeting, with panelists and other observers protesting the unexpected results and the ethics of the unique study design. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 2, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

ACC: HEAT PPCI Burns Angiomax (CME/CE)
WASHINGTON (MedPage Today) -- In a head-to-head comparison of bivaliruden (Angiomax) and heparin in more than 1,800 patients stented for acute MI, heparin was the clear winner. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 1, 2014 Category: Cardiology Source Type: news

Hemorrhagic Risk and Bivalirudin vs UFH in PCIHemorrhagic Risk and Bivalirudin vs UFH in PCI
What's the impact of bivalirudin compared with UFH on the rates of mortality, myocardial infarction, and major bleeding? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 24, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

The Medicines Company's EUROMAX trial of Angiox(r) (bivalirudin) in heart attack meets all prespecified endpoints
The Medicines Company (NASDAQ: MDCO) today announced results from the EUROMAX Trial, a 2,218 patient Phase IIIb randomized study of the Company's Angiox® (bivalirudin), which is marketed as Angiomax® (bivalirudin) in the US. The trial met its pre-specified primary and secondary endpoints, including statistically significant reductions in the primary composite endpoint of death and major bleeding among patients randomized to Angiox... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 1, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Bivalirudin for heart attack soon to be available for emergency teams and ambulances
A new strategy for emergency anticoagulant treatment for patients with acute myocardial infarction has been put in place by a team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at Hopital Bichat, AP-HP, Universite Paris Diderot). These results from the EUROMAX clinical trial are published in The New England Journal of Medicine. Myocardial infarction, commonly called "heart attack," remains the leading cause of death worldwide, and affects nearly 100,000 individuals a year in France... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 1, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

EUROMAX Meets Primary Endpoint But Editorialist Raises Questions
When started during transport to the hospital during a heart attack, bivalirudin (Angiox, Medicines Company) improves clinical outcomes and reduces major bleeding, though at the cost of a small but significant risk in stent thrombosis. The results of the European Ambulance Acute Coronary Syndrome (ACS) Angiography) Trial (EUROMAX) were presented today by Phillippe Gabriel Steg at the TCT conference in San Francisco and published simultaneously in the New England Journal of Medicine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 30, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Medicines Co blood thinner cuts death risk in European ambulance trial
(Reuters) - Medicines Co's blood thinner Angiomax, when administered en route to the hospital to patients suffering a serious heart attack, significantly reduced the risk of major bleeding and death compared with commonly used heparin, according to data from a large clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - October 30, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Bleed Risk Falls with Bivalirudin en Route to PCI for STEMIBleed Risk Falls with Bivalirudin en Route to PCI for STEMI
Some will recognize shades of HORIZONS AMI: the gains came from bivalirudin vs heparin or enoxaparin for STEMI, initiated in EUROMAX while patients were in an ambulance en route to a PCI center. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

TCT: Bivalirudin Beneficial in EUROMAX
SAN FRANCISCO (MedPage Today) -- Initiating bivalirudin (Angiomax) treatment in the ambulance significantly reduced major bleeding and/or death at 30 days in ST-elevation MI patients undergoing PCI, but at increased risk of stent thrombosis, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 30, 2013 Category: Cardiology Source Type: news

Study finds pre-hospital administration of bivalirudin substantially improves outcomes compared to heparin in heart attack patients
(Cardiovascular Research Foundation) According to a new study, administering the blood thinner bivalirudin to patients experiencing an ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) in a pre-hospital setting can reduce the risk of death and major bleeding complications compared to heparin with optional use of glycoprotein IIb/IIIa inhibitors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2013 Category: Global & Universal Source Type: news

Bivalirudin Has Benefit Beyond Clotting Effect (CME/CE)
(MedPage Today) -- In patients undergoing PCI for ST-segment elevation myocardial infarction, the direct thrombin inhibitor bivalirudin (Angiomax) reduced cardiac mortality independent of its effects on major bleeding. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 18, 2013 Category: Primary Care Source Type: news

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involving the e...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

Bivalirudin linked to less bleeding, but more severe complications, vs. eptifibatide
Read the full story on MD Consult: Bivalirudin linked to less bleeding, but more severe complications, vs. eptifibatide (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - August 23, 2013 Category: Journals (General) Source Type: news

Superiority Of Bivalirudin Over Heparin Questioned
Results from a large observational study reported at EuroPCR 2013 question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). European and US NSTE-ACS guidelines currently recommend bivalirudin alone as an alternative to unfractionated heparin plus GP IIb/IIIa receptor inhibitors in patients undergoing an intended urgent or early invasive strategy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 24, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Bivalirudin Needs Closer Look in ACS, Study Suggests (CME/CE)
PARIS (MedPage Today) -- Whether clinicians chose bivalirudin (Angiomax) or heparin as monotherapy made no difference in outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing PCI, a registry study showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 22, 2013 Category: Consumer Health News Source Type: news